Integrative genome-scale studies of UL harboring different driver genetic alterations, including those in MED12 and HMGA2 contributing to 80–90% of leiomyomas, have uncovered UL subtypes gene expression signatures8. This evidence concerns the gene HMGA2 and uterine corpus leiomyoma.